MétaCan
Menu
Back to cohort
Record W4226062860 · doi:10.1177/17562864211058298

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice

2021· review· en· W4226062860 on OpenAlexafffund
Diego Centonze, Gavin Giovannoni, Le H. Hua, Celia Oreja‐Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout

Bibliographic record

VenueTherapeutic Advances in Neurological Disorders · 2021
Typereview
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsUniversity of TorontoSt. Michael's Hospital
FundersEMD SeronoMedDay PharmaceuticalsGenentechSerono Symposia International FoundationServierAristotle University of ThessalonikiPirogov Russian National Research Medical UniversityMedizinische Universität WienRigshospitaletUniversità degli Studi di GenovaHebrew University of JerusalemUniversität WienQueen Mary University of LondonCSL BehringGentofte HospitalFresenius Medical Care North AmericaFive Prime TherapeuticsIronwood Pharmaceuticals, IncorporatedVertex PharmaceuticalsOttawa Hospital Research InstituteBayer VitalBristol-Myers SquibbBundesministerium für Bildung und ForschungAtara BiotherapeuticsMerck KGaAUniverzita Karlova v PrazePfizerBiogenCelgeneTeva Pharmaceutical IndustriesSanofiGW PharmaceuticalsUniversità degli Studi di Napoli Federico IIBayer HealthCareDeutsche ForschungsgemeinschaftDirectorate for Biological SciencesGlaxoSmithKline
KeywordsCladribineMedicineExpert opinionVaccinationCoronavirus disease 2019 (COVID-19)Clinical PracticeDosingMEDLINEMultiple sclerosisFamily medicineIntensive care medicinePharmacologyInternal medicinePathologyImmunologyDiseaseInfectious disease (medical specialty)

Abstract

fetched live from OpenAlex

BACKGROUND: Gaps in current evidence and guidance leave clinicians with unanswered questions on the use of cladribine tablets for the treatment of multiple sclerosis (MS) in the era of the COVID-19 pandemic, in particular relating to COVID-19 vaccination. OBJECTIVE: We describe a consensus-based program led by international MS experts with the aim of supplementing current guidelines and treatment labels by providing timely recommendations relating to COVID-19 vaccination and the use of cladribine tablets in clinical practice. METHODS: A steering committee (SC) of 10 international MS experts identified 7 clinical questions to answer concerning the use of cladribine tablets and COVID-19 vaccination, which addressed issues relating to patient selection, timing and efficacy, and safety. Clinical recommendations to address each question were drafted using available evidence combined with expert opinion from the SC. An extended faculty of 28 MS experts, representing 19 countries, in addition to the 10 SC members, voted on the recommendations. Consensus on recommendations was achieved when ⩾75% of respondents expressed an agreement score of 7-9, on a 9-point scale. RESULTS: Consensus was achieved on all 13 recommendations. Clinical recommendations are provided on whether all patients with MS receiving cladribine tablets should be vaccinated against COVID-19, and whether they should be prioritized; the timing of vaccination around dosing of cladribine tablets (i.e. before and after a treatment course); and the safety of COVID-19 vaccination for these patients. CONCLUSION: These expert recommendations provide timely guidance on COVID-19 vaccination in patients receiving cladribine tablets, which is relevant to everyday clinical practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.023
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.995
Threshold uncertainty score0.985

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.023
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.319
GPT teacher head0.528
Teacher spread0.209 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueTherapeutic Advances in Neurological DisordersSame topicMultiple Sclerosis Research StudiesFrench-language works237,207